

Medical Policies

Policy Title	Summary	Products Affected	Effective Date
Abecma (MGBHP)	Annual review. <ul style="list-style-type: none"> Reformatted policy. Updated criteria to match FDA label. Edited language in duals section. Abecma.pdf 	Medicare Advantage and Duals	3/1/2026
Acupuncture	Ad hoc review. <ul style="list-style-type: none"> Reformatted policy. Removed reference to custom IQ subset; custom IQ subset retired. Edited language in duals section. Acupuncture.pdf 	All products	3/1/2026
Aucatzyl (MGBHP)	Annual review. <ul style="list-style-type: none"> Reformatted policy. Updated criteria to match FDA label. Edited language in duals section. Aucatzyl.pdf 	Medicare Advantage and Duals	3/1/2026
Autologous Chondrocyte Implantation in the Knee	Ad hoc review. <ul style="list-style-type: none"> Reformatted policy. Removed reference to custom IQ subset; custom IQ subset retired. Edited language in duals section. AutologousChondrocyteImplantationintheKnee.pdf 	All products	3/1/2026
Breyanzi (MGBHP)	Annual review. Material change. <ul style="list-style-type: none"> Reformatted policy. Updated criteria to match FDA label and added indication for marginal zone lymphoma. Edited language in duals section. Breyanzi.pdf 	Medicare Advantage and Duals	3/1/2026
Carvykti (MGBHP)	Annual review. <ul style="list-style-type: none"> Reformatted policy. Updated criteria to match FDA label. 	Medicare Advantage and Duals	3/1/2026

	<ul style="list-style-type: none"> • Edited language in duals section. • carvykti.pdf 		
Elevydis (MGBHP)	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated PA process in commercial section. • Edited language in duals section. • ElevidysApr2026.pdf 	Commercial and Duals	4/1/2026
Encelto (MGBHP)	<p>New policy. Material change.</p> <ul style="list-style-type: none"> • Encelto.pdf 	All products	4/1/2026
Encelto (Prime Therapeutics)	<p>New policy. Material change.</p> <ul style="list-style-type: none"> • Upcoming drug policies managed by Prime Therapeutics can be found here: Gateway 	Commercial and QHP	4/1/2026
Hearing Devices	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subsets; custom IQ subsets retired. • Edited language in duals section. • HearingDevices.pdf 	All products	3/1/2026
Kebilidi (MGBHP)	<p>New policy. Material change.</p> <ul style="list-style-type: none"> • Kebilidi.pdf 	All products	4/1/2026
Kebilidi (Prime Therapeutics)	<p>New policy. Material change.</p> <ul style="list-style-type: none"> • Upcoming drug policies managed by Prime Therapeutics can be found here: Gateway 	Commercial and QHP	4/1/2026
Kymriah (MGBHP)	<p>Annual review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated criteria to match FDA label. • Edited language in duals section. • Kymriah.pdf 	Medicare and Duals	3/1/2026
Liposuction to Treat Lipedema and Lymphedema	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subset; custom IQ subset retired. • Edited language in duals section. 	All products	3/1/2026

	<ul style="list-style-type: none"> • LiposuctionLipedemaLymphedema.pdf 		
Medically Necessary Services	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Added evidence hierarchy from E&I policy. • Added ACO section. • MedicallyNecessary.pdf 	All products	4/1/2026
Phototherapeutic Keratectomy	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subset; custom IQ subset retired. • Edited language in duals section. • PhototherapeuticKeratectomy.pdf 	All products	3/1/2026
Prostheses – Upper Limb	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subset; custom IQ subset retired. • Edited language in duals section. • Prostheses-UpperLimb.pdf 	All products	3/1/2026
Reconstructive and Cosmetic Procedures	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed references to custom IQ subsets; custom IQ subsets retired. • Edited language in duals section. • ReconstructiveandCosmeticProcedures.pdf 	All products	3/1/2026
Skysona (MGBHP)	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated PA process in commercial section. • Edited language in duals section. • SkysonaApr2026.pdf 	Commercial and Duals	4/1/2026
Tecartus (MGBHP)	<p>Annual review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated criteria to match FDA label. • Edited language in duals section. 	Medicare Advantage and Duals	3/1/2026

	<ul style="list-style-type: none"> • Tecartus.pdf 		
Tecelra (MGBHP)	<p>Annual review. Material change.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated criteria to match FDA label. This changed the age of eligibility from 16 to 18 years of age. • Edited language in duals section. • TecelraMay2026.pdf 	Medicare Advantage and Duals	5/1/2026
Therapeutic Lens	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subset; custom IQ subset retired. • Edited language in duals section. • TherapeuticLens.pdf 	All products	3/1/2026
UVB Home Phototherapy Units for Skin Disease	<p>Ad hoc review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Removed reference to custom IQ subset; custom IQ subset retired. • Edited language in duals section. • UVBHomePhototherapyforSkinDisease.pdf 	All products	3/1/2026
Yescarta (MGBHP)	<p>Annual review.</p> <ul style="list-style-type: none"> • Reformatted policy. • Updated criteria to match FDA label. • Edited language in duals section. • Yescarta.pdf 	Medicare Advantage and Duals	3/1/2026
Zevaskyn (MGBHP)	<p>New policy. Material change.</p> <ul style="list-style-type: none"> • Zevaskyn.pdf 	All products	3/1/2026